Profile data is unavailable for this security.
About the company
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anaemia. The Company operates through two segments: Feraccru (ferric maltol), and PT20. Its lead product Accrufer/Feraccru is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, United Kingdom, and Switzerland for the treatment of iron deficiency with or without anemia in adults. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
- Revenue in GBP (TTM)20.88m
- Net income in GBP-36.17m
- Incorporated2015
- Employees73.00
- LocationShield Therapeutics PLC3rd FlBaltic Business Quarters, Abbott's HillGATESHEAD NE8 3DUnited KingdomGBR
- Phone+44 191 511 8500
- Websitehttps://www.shieldtherapeutics.com/